Children receiving intermediate, high dose MTX experience poor CINV control
the ONA take:
Children with cancer receiving methotrexate had a poor complete chemotherapy-induced nausea and vomiting (CINV) rate, both in the acute and delayed phases, according to a new study published in the journal Supportive Care in Cancer.
For the prospective study, 30 children received intermediate-dose (ID-MTX: >1 to <12/g/m2/dose) or high-dose methotrexate (HD-MTX: ≥12 g/m2/dose). CINV prophylaxis was provided to pediatric patients at the discretion of the clinician.
Researchers documented antiemetic administration, nausea severity, and emetic episodes during the acute phase (for 24 hours from the start of the methotrexate infusion) and the delayed phase (for up to a further 168 hours).
Researchers found that CINV prophylaxis received ondansetron or granisetron plus dexamethasone or nabilone. Results showed that among the 10 patients that received HD-MTX, 0% achieved complete control during the acute phase and 30% experienced complete control in the delayed phase.
Among the 20 patients that received ID-MTX, the complete control rates were 20% and 5% in the acute and delayed phase, respectively.
The findings confirm the classification of HD-MTX as highly emetogenic chemotherapy and suggest that ID-be reclassified as highly emetogenic chemotherapy, as well.
Children with cancer receiving methotrexate had a poor complete chemotherapy-induced nausea and vomiting (CINV) rate.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
- Direct-to-Consumer Genetic Test for Select BRCA Mutations Gets FDA Nod
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|